Copenhagen - Free Realtime Quote DKK

Coloplast A/S (COLO-B.CO)

900.40 +4.20 (+0.47%)
As of 12:32 PM GMT+2. Market Open.
Loading Chart for COLO-B.CO
DELL
  • Previous Close 896.20
  • Open 896.00
  • Bid 900.20 x --
  • Ask 900.60 x --
  • Day's Range 895.20 - 905.20
  • 52 Week Range 689.20 - 993.00
  • Volume 26,682
  • Avg. Volume 233,910
  • Market Cap (intraday) 202.432B
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) 40.34
  • EPS (TTM) 22.32
  • Earnings Date May 7, 2024
  • Forward Dividend & Yield 21.00 (2.34%)
  • Ex-Dividend Date Dec 8, 2023
  • 1y Target Est 940.00

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

www.coloplast.com

15,751

Full Time Employees

September 30

Fiscal Year Ends

Recent News: COLO-B.CO

Performance Overview: COLO-B.CO

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

COLO-B.CO
16.63%
OMX Copenhagen 25 Index
3.08%

1-Year Return

COLO-B.CO
3.52%
OMX Copenhagen 25 Index
1.61%

3-Year Return

COLO-B.CO
3.07%
OMX Copenhagen 25 Index
8.02%

5-Year Return

COLO-B.CO
46.51%
OMX Copenhagen 25 Index
0.00%

Compare To: COLO-B.CO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: COLO-B.CO

Valuation Measures

As of 4/18/2024
  • Market Cap

    201.49B

  • Enterprise Value

    222.20B

  • Trailing P/E

    40.22

  • Forward P/E

    36.90

  • PEG Ratio (5yr expected)

    3.43

  • Price/Sales (ttm)

    7.78

  • Price/Book (mrq)

    13.32

  • Enterprise Value/Revenue

    8.89

  • Enterprise Value/EBITDA

    27.92

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.47%

  • Return on Assets (ttm)

    10.29%

  • Return on Equity (ttm)

    46.30%

  • Revenue (ttm)

    25B

  • Net Income Avi to Common (ttm)

    4.87B

  • Diluted EPS (ttm)

    22.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    916M

  • Total Debt/Equity (mrq)

    143.01%

  • Levered Free Cash Flow (ttm)

    7.24B

Research Analysis: COLO-B.CO

Analyst Price Targets

700.00 Low
940.00 Average
900.40 Current
1,290.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch